Home > Publications Database > Akinetic crisis and withdrawal syndromes: guideline 'Parkinson's disease' of the German Society of Neurology. > print

001     272581
005     20250314091251.0
024 7 _ |a 10.1007/s00415-024-12649-x
|2 doi
024 7 _ |a pmid:39192030
|2 pmid
024 7 _ |a pmc:PMC11447035
|2 pmc
024 7 _ |a 0367-004X
|2 ISSN
024 7 _ |a 0012-1037
|2 ISSN
024 7 _ |a 0340-5354
|2 ISSN
024 7 _ |a 1432-1459
|2 ISSN
037 _ _ |a DZNE-2024-01202
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pötter-Nerger, Monika
|0 0000-0001-7680-2147
|b 0
245 _ _ |a Akinetic crisis and withdrawal syndromes: guideline 'Parkinson's disease' of the German Society of Neurology.
260 _ _ |a Heidelberg
|c 2024
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1729170220_2185
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The akinetic crisis is a well-known, rare, potentially life-threatening condition in Parkinson's disease with subacute worsening of akinesia, rigidity, fever, impaired consciousness, accompanying vegetative symptoms and transient dopa-resistance. The akinetic crisis was historically supposed to be a 'withdrawal syndrome' in the sense of discontinuation of dopaminergic medication. Recently, other 'withdrawal syndromes' as the specific 'dopamine agonist withdrawal syndrome' or 'deep brain stimulation withdrawal syndrome' have been described as emergency situations with specific subacute symptom constellations. All three conditions require immediate start of the adequate therapy to improve the prognosis. Here, the diagnostic criteria and treatment options of these three acute, severely disabling syndromes will be reported along the current guidelines of the German Parkinson Guideline Group.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Akinetic crisis
|2 Other
650 _ 7 |a Deep brain stimulation withdrawal syndrome
|2 Other
650 _ 7 |a Diagnostic criteria
|2 Other
650 _ 7 |a Dopamine agonist withdrawal syndrome
|2 Other
650 _ 7 |a German Parkinson Guideline
|2 Other
650 _ 7 |a Therapy
|2 Other
650 _ 7 |a Antiparkinson Agents
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: drug therapy
|2 MeSH
650 _ 2 |a Parkinson Disease: diagnosis
|2 MeSH
650 _ 2 |a Parkinson Disease: therapy
|2 MeSH
650 _ 2 |a Substance Withdrawal Syndrome: diagnosis
|2 MeSH
650 _ 2 |a Germany
|2 MeSH
650 _ 2 |a Neurology: standards
|2 MeSH
650 _ 2 |a Societies, Medical: standards
|2 MeSH
650 _ 2 |a Antiparkinson Agents: therapeutic use
|2 MeSH
650 _ 2 |a Antiparkinson Agents: adverse effects
|2 MeSH
650 _ 2 |a Deep Brain Stimulation: standards
|2 MeSH
650 _ 2 |a Practice Guidelines as Topic: standards
|2 MeSH
700 1 _ |a Löhle, Matthias
|0 P:(DE-2719)2813524
|b 1
|u dzne
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 2
|e Last author
|u dzne
700 1 _ |a Group, German Parkinson‘s Guideline
|b 3
|e Collaboration Author
773 _ _ |a 10.1007/s00415-024-12649-x
|g Vol. 271, no. 10, p. 6485 - 6493
|0 PERI:(DE-600)1421299-7
|n 10
|p 6485 - 6493
|t Journal of neurology
|v 271
|y 2024
|x 0367-004X
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/272581/files/DZNE-2024-01202.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/272581/files/DZNE-2024-01202.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:272581
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2813524
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811373
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J NEUROL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J NEUROL : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger
|l Translational Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1110002
980 _ _ |a I:(DE-2719)1510100
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21